Bionano Announces Robust Presence at Upcoming Cytogenetics Conferences ESHG and ACC with 39 Scientific Presentations and Posters Highlighting the Utility of the Optical Genome Mapping Workflow
May 30 2024 - 7:00AM
Bionano Genomics, Inc. (Nasdaq: BNGO) today announced the Company’s
robust participation at two upcoming cytogenetics conferences, the
2024 European Society for Human Genetics (ESHG) Annual Conference
and the 2024 American Cytogenomics Conference (ACC), with a record
39 scientific presentations and posters across the two conferences
that highlight the utility of the Company’s OGM workflow for
applications in genetic disease, cancer, and rare disease research
and discussing the latest advances to the Company’s suite of
products, including the high throughput Stratys system and VIA
software.
ESHG brings together industry and academic professionals
annually to discuss new technologies and advances in the field of
human genetics. ESHG sessions will take place June 1-4, 2024
virtually and in Berlin, Germany.
ACC is a biennial conference focused on new technologies and
advances in the field of cytogenetics. ACC will be held June 2-5,
2024 in Norfolk, Virginia.
Bionano will host a sponsored session at ESHG featuring an
overview of the Company’s OGM workflow delivered by Bionano’s chief
medical officer, Dr. Alka Chaubey, a presentation from Dr. Laura
Batlle Masó at Vall d’Hebron Institute of Research (Spain) on OGM’s
potential utility in resolving hereditary angioedema (HAE) cases, a
presentation from Dr. Bart van der Sanden at Radboud UMC
(Netherlands) covering how OGM may be useful for the detection
of SVs relevant to rare disease, and a presentation from Marlene Ek
at Karolinska Institute (Sweden) highlighting OGM’s ability to
unveil more cytogenomic insights into multiple myeloma samples than
traditional cytogenetic methods.
At ACC, a sponsored session will feature Dr. Mike
Gallagher, market development manager at Bionano, highlighting
OGM’s ability to enhance detection of pathogenic variants and to
advance genetic disease research. Dr. Gallagher will also introduce
the latest innovations in the OGM workflow, including the Stratys
system and VIA software.
Erik Holmlin, PhD, president and chief executive officer of
Bionano, stated, “We are excited to see the progress that the
global OGM community is making, which is highlighted by the growth
in the number of scientific posters and presentations on OGM from
the last time the ESHG and ACC conferences were held. We believe
this expansion demonstrates the increased customer adoption of OGM,
with routine and repeated utilization for innovative research into
genetic disorders, cancer and rare disease.”
ESHG scientific presentations and poster
sessions:
Scientific presentations and poster sessions on OGM at ESHG take
place in the exhibition halls unless otherwise noted.
Abstract/ Poster
Number |
Title |
Authors |
Presented |
P14.015.A |
Deciphering a complex short size RERE rearrangement: importance of
combined approaches for duplication interpretation |
Fauqueux J. |
June 2, 202410:15-11:15 AM CEST |
P01.065.A |
A Canadian lab’s experience using optical genome mapping to
clinically genotype hematological neoplasms |
Hamadeh Z. |
June 2, 202410:15-11:15 AM CEST |
P03.025.A |
Characterization of a complex rearrangement between three
chromosomes in a fetus with skeletal anomalies by optical genome
mapping |
Heinrich U. |
June 2, 202410:15-11:15 AM CEST |
P16.077.A |
Accurate identification of pathogenic structural variants guided by
multi-platform comparison |
Moeinzadeh M. |
June 2, 202410:15-11:15 CEST |
P01.163.B |
Deciphering the molecular complexity of the IKZF1 plus profile
using optical genome mapping |
Lühmann J. |
June 2, 202416:45-17:45 PM CEST |
P12.023.B |
SORD and SORD2P inversion: long read sequencing identifies a novel
genetic mechanism underlying inherited neuropathy |
Manini A. |
June 2, 202416:45-17:45 PM CEST |
P04.029.B |
Optical genome mapping facilitates rapid characterization of
structural variants in families with developmental eye
anomalies |
Merepa S. |
June 2, 202416:45-17:45 PM CEST |
P01.007.C |
Large genomic rearrangement: tandem duplication and triplication in
BRCA1 gene causative for hereditary breast and ovarian cancer |
Aldrige Allister B. |
June 3, 202410:15-11:15 AM CEST |
P15.102.C |
Establishing ultra-rapid genome sequencing in neonatal and
pediatric intensive care units in Germany – project Baby Lion |
Auber B. |
June 3, 202410:15-11:15 AM CEST |
P14.029.C |
Optical genome mapping of a patient with ring chromosome 3 shows
the importance of choosing the proper reference genome for the
analysis |
Burssed B. |
June 3, 202410:15-11:15 AM CEST |
P14.025.C |
Positive predictive value of balanced structural variants reported
through short-read genome sequencing: do we need orthogonal
confirmation? |
Chatron N. |
June 3, 202410:15-11:15 AM CEST |
P14.013.C |
Optical genome mapping identifies hidden structural variants in 58
undiagnosed rare disease patient-parent trios |
Hoischen A. |
June 3, 202410:15-11:15 AM CEST |
P01.160.C |
Deciphering copy number variations within the complex genomic
region of the PMS2 gene using optical genome mapping |
Maier J. |
June 3, 202410:15-11:15 AM CEST |
P12.032.C |
The WWOX gene variants detection in patient with cerebellar ataxia
using optical genome mapping |
Rutkowska K. |
June 3, 202410:15-11:15 AM CEST |
P01.051.C |
Enhanced cytogenomic analysis of complex karyotype in
myelodysplastic syndrome using optical genome mapping |
Valkama A. |
June 3, 202410:15-11:15 AM CEST |
P21.065.D |
Advancing genetic diagnostics: optical genome mapping’s efficacy in
identifying structural variants for autosomal recessive
diseases |
Beyza Ogutlu O. |
June 3, 202416:45-17:45 PM CEST |
P15.079.D |
Benefits of the analysis of a complex chromosomal rearrangement in
the implementation of long read approaches |
Chambon P. |
June 3, 202416:45-17:45 PM CEST |
P04.011.D |
A combined approach of innovative DNA- and RNA-technologies reveals
hidden LINE-1/ERV insertion in IQCB1 as causative variant for
Senior Løken syndrome |
de Bruijn S. |
June 3, 202416:45-17:45 PM CEST |
P01.056.D |
Exome sequencing identified rare recurrent copy number variants and
hereditary breast cancer susceptibility |
Mantere T. |
June 3, 202416:45-17:45 PM CEST |
P15.091.D |
A multimodal approach to molecular diagnosis in NF1 highlights the
need for bespoke analysis in undiagnosed patients |
McAleese-Park E. |
June 3, 202416:45-17:45 PM CEST |
P10.021.D |
Optical genome mapping finally unveils the genetic cause of
aniridia and intellectual disability in a 17-year-old after seven
years of diagnostic odyssey |
Telman W. |
June 3, 202416:45-17:45 PM CEST |
E-poster |
Optical genome mapping for comprehensive genomic rearrangement
analysis |
Flunkert J. |
Online |
E-poster |
Optical genome mapping: lighting the way in complex clinical
cases |
Monge Lobo I. |
Online |
E-poster |
Refining genotype-phenotype correlation in complex chromosomal
rearrangements using optical genome mapping – case report |
Vallova V. |
Online |
E-poster |
Unraveling the mysteries of balanced rearrangements: optical genome
mapping spotlights BCL11B misregulation in a familial
translocation |
Alcalá San Martín A. |
Online |
E-poster |
Optical genome mapping (OGM) allows the characterization of a
complex chromosome rearrangement associated with recurrent
pregnancy loss |
Trost D. |
Online |
E-poster |
Focus on deletions and duplications identified by optical genome
mapping technique in a cohort of 100 patients: comparison with
MCA |
Doco-Fenzy M. |
Online |
Room |
Title |
Presenter |
Presented |
Poster presentation |
Optical genome mapping identifies hidden structural variants in
previously undiagnosed rare disease cases in Solve-RD |
van der Sanden B. |
June 1, 202419:00-19:15 PM CEST, Room A8 |
Poster presentation |
Multiomics and deep phenotyping in MECP2 Duplication syndrome:
insight into disease severity, expression variability, and nucleic
acid therapeutics |
Pehlivan D. |
June 1, 202419:45-20:00 PM CEST, Room A8 |
Poster presentation |
Next generation cytogenetics by optical genome mapping |
Kanagal-Shamanna R. |
June 3, 202408:30-10:00 AM CEST, Room A2 |
Sponsored session |
Insights into constitutional disorders and beyond: scaling to new
heights with optical genome mapping |
Chaubey A., Batlle Masó L., van der Sanden B., Ek M. |
June 3, 202414:00-15:30 PM CESTRoom New York 3 (Level 1) |
ACC scientific presentations and poster
sessions:
Scientific presentations and poster sessions on OGM at ACC take
place in the exhibition hall.
Poster/Presentation |
Title |
Presenter |
Presented |
Exhibitor theater session |
Revolutionizing cytogenomics with optical genome mapping:
high-resolution structural variant detection with an elevated
sample-to-answer workflow |
Gallagher M. |
June 3, 202412:15-12:35 PM EST |
Poster presentation |
Enhanced detection of primary oncogenic drivers in pediatric
T-lymphoblastic leukemia (T-ALL) by optical genome mapping
(OGM) |
Raca G. |
June 3, 20242:00-2:15 PM EST |
Poster presentation |
Utility of optical genome mapping as an additional tool to standard
cytogenetic workup in hematological malignancies |
Toruner G. |
June 3, 20242:15-2:30 PM EST |
Poster presentation |
A curated research catalogue of structural variation from 809
postnatal cases detected by optical genome mapping |
Pang A. |
June 3, 20244:00-4:15 PM EST |
Poster presentation |
A search for genetic determinants in neural tube defects using
optical genome mapping |
Sahajpal N. |
June 3, 20244:15-4:30 PM EST |
Poster presentation |
Cross-comparison of optical genome mapping and chromosomal
microarray data using VIA software |
Yu J. |
June 3, 20244:30-4:45 PM EST |
Poster hall |
Efficient hematological malignancy analysis and reporting workflow
using optical genome mapping |
Clifford B. |
|
Poster hall |
Isotachophoresis (ITP) for high-throughput isolation of UHMW gDNA
suitable for optical genome mapping (OGM) |
Yadav M. |
|
More details on Bionano’s presence at the ESHG conference can be
found here, and virtual posters will be shown here; more details on
Bionano’s presence at the ACC conference can be found here.
About Bionano
Bionano is a provider of genome analysis solutions that can
enable researchers and clinicians to reveal answers to challenging
questions in biology and medicine. The Company’s mission is to
transform the way the world sees the genome through OGM solutions,
diagnostic services and software. The Company offers OGM solutions
for applications across basic, translational and clinical research.
The Company also offers an industry-leading, platform-agnostic
genome analysis software solution and nucleic acid extraction and
purification solutions using proprietary isotachophoresis (ITP)
technology. Through its Lineagen, Inc. d/b/a Bionano
Laboratories business, the Company also offers OGM-based
diagnostic testing services. For more information,
visit www.bionano.com, www.bionanolaboratories.com or www.purigenbio.com.
Unless specifically noted otherwise, Bionano’s OGM products
are for research use only and not for use in diagnostic
procedures.
Forward-Looking Statements of Bionano
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995. Words such as “ability,” “believe,” “may,” “potential,”
“will,” and similar expressions (as well as other words or
expressions referencing future events, conditions or circumstances)
convey uncertainty of future events or outcomes and are intended to
identify these forward-looking statements. Forward-looking
statements include statements regarding our intentions, beliefs,
projections, outlook, analyses or current expectations concerning,
among other things, OGM’s utility for genetic disorder, rare
disease, and cancer research applications; OGM’s ability and
utility for resolving HAE cases; the ability and utility of OGM to
detect SVs relevant to rare disease; the ability of OGM to unveil
more cytogenomic insights into multiple myeloma samples than
traditional cytogenetic methods; OGM’s ability to enhance detection
of pathogenic variants and to advance genetic disease research; the
utility of the latest innovations in OGM workflows, including the
Stratys system and VIA software; the utility of OGM for research in
the areas reported in the presentations given and the posters made
available at the ESHG Annual Conference 2024 and AAC 2024; the
growth and adoption of OGM for use in genetic disorder, rare
disease, and cancer research applications; the ability and utility
of our OGM solutions to drive market adoption of OGM; and any other
statements not of historical fact. Each of these forward-looking
statements involves risks and uncertainties. Actual results or
developments may differ materially from those projected or implied
in these forward-looking statements. Factors that may cause such a
difference include the risks and uncertainties associated with:
global and macroeconomic events, such as the impact of the global
pandemics, bank failures, interest rate changes, supply
disruptions, and the ongoing conflicts in the Ukraine and Russia
and between Israel and Hamas, and related sanctions, on our
business and the global economy; general market conditions; changes
in the competitive landscape and the introduction of competitive
technologies or improvements to existing technologies; the failure
of OGM’s utility for genetic disorder, rare disease, and cancer
research applications; the failure of OGM to resolve HAE cases; the
failure of OGM to detect SVs relevant to rare disease; the failure
of OGM to unveil more cytogenomic insights into multiple myeloma
samples than traditional cytogenetic methods; the failure of OGM to
enhance detection of pathogenic variants and to advance genetic
disease research; the failure of our latest innovations in OGM
workflows, including the Stratys system and VIA software; the
failure of OGM for research in the areas reported in the
presentations given and the posters made available at the ESHG
Annual Conference 2024 and AAC 2024; the growth and adoption of OGM
for use in genetic disorder, rare disease, and cancer research
applications; the ability and utility of our OGM solutions to drive
market adoption of OGM; the ability of our OGM solutions to offer
the anticipated benefits for and contributions to the areas
reported in the presentations given and posters made available at
the ESHG Annual Conference 2024 and AAC 2024; future study results
contradicting the results reported in the presentations given and
posters made available at the ESHG Annual Conference 2024 and AAC
2024; changes in our strategic and commercial plans; our ability to
obtain sufficient financing to fund our strategic plans and
commercialization efforts; the ability of medical and research
institutions to obtain funding to support adoption or continued use
of our technologies; our ability to obtain sufficient financing to
fund our strategic plans and commercialization efforts and to
continue as a "going concern”; and the risks and uncertainties
associated with our business and financial condition in general,
including the risks and uncertainties described in our filings with
the Securities and Exchange Commission, including, without
limitation, our Annual Report on Form 10-K for the year ended
December 31, 2023 and in other filings subsequently made by us with
the Securities and Exchange Commission. All forward-looking
statements contained in this press release speak only as of the
date on which they were made and are based on management’s
assumptions and estimates as of such date. We do not undertake any
obligation to publicly update any forward-looking statements,
whether as a result of the receipt of new information, the
occurrence of future events or otherwise.
CONTACTS
Company Contact:Erik Holmlin, CEOBionano
Genomics, Inc.+1 (858) 888-7610eholmlin@bionano.com
Investor Relations:David HolmesGilmartin
Group+1 (858) 888-7625IR@bionano.com
Bionano Genomics (NASDAQ:BNGO)
Historical Stock Chart
From May 2024 to Jun 2024
Bionano Genomics (NASDAQ:BNGO)
Historical Stock Chart
From Jun 2023 to Jun 2024